Background {#Sec1}
==========

Diabetes mellitus (DM) has been categorized as a complex and multifactorial metabolic condition \[[@CR1]\]. Many factors play important roles in the development of glucose intolerance in individuals with type 2 diabetes (T2D), such as impaired insulin secretion and insulin resistance \[[@CR2], [@CR3]\]. It is widely accepted that the gold standard method for evaluating insulin action is hyperinsulinemic-euglycemic clamp \[[@CR4]\]. Because this method is invasive, complicated, and expensive, its application in clinical practice is limited. The oral glucose tolerance test (OGTT) has been used to diagnose diabetes or to capture the impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) based on the fasting plasma glucose (FPG) and 2-h plasma glucose (2hPG) \[[@CR5]\]. Although β-cell function and insulin action can be obtained through calculating a series of formulas, such as the insulinogenic index or Matsuda Index during the OGTT, they are not intuitive. The OGTT glucose response curve could be a novel and intuitive biomarker to identify early metabolic risk \[[@CR6]\]. Recent cross-sectional studies \[[@CR6]--[@CR13]\] showed that OGTT response curves, either monophasic or biphasic, can not only indicate β-cell function and insulin resistance but also differentiate diabetes risk. Those studies revealed that individuals with a monophasic curve tended to have worse insulin sensitivity and β-cell function. A recent prospective study demonstrated that individuals with a biphasic curve developed T2D at a lower rate than those with a monophasic curve, independent of FPG and/or 2hPG \[[@CR14]\].

However, the scale of these studies was generally small, with a maximum of hundreds of subjects included, and only one study was conducted in an Asian population \[[@CR11]\]. These studies mainly focused on people without diabetes. No studies showed a relationship between age and the shape of the glucose response curve. In addition, few studies reported the dynamic change of glucose response curves and their relationship with baseline β-cell function and insulin sensitivity.

Therefore, the purposes of this study were as follows: 1) to verify the utility of the OGTT glucose response curve in predicting β-cell function and insulin sensitivity in a large Chinese population with varying statuses of glucose tolerance; 2) to examine the relationship between age and the shape of glucose response curves; and 3) to assess if the shape of glucose response curves changed dynamically over time and whether the change was related to baseline β-cell function and insulin sensitivity.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

We retrospectively analyzed data of individuals who were tested with a 3-h OGTT and with complete glucose and insulin testing in Peking Union Medical College Hospital from August 2011 to January 2018. Participants were excluded from the study if any of the following criteria were met: a) missing demographic information (age or sex); b) under 18 years old and over 18 years old who did not receive 75 g glucose for OGTT; c) FPG \< 3.9 mmol/L; d) history of diabetes; e) FINS \> 60 μIU/ml or serum insulin level \> 300 μIU/ml at any point of OGTT, because the upper limit was 300 μIU/ml; e) 30-min plasma glucose ≤0-min plasma glucose or 30-min serum insulin ≤0-min serum insulin, to ensure insulinogenic index could be calculated; and g) shapes of the curve could not be classified.

Blood sampling and OGTT {#Sec4}
-----------------------

After an overnight fast, participants underwent a 3-h OGTT with the ingestion of 75 g glucose. Venous blood samples were obtained at 0, 30, 60, 120, and 180 min. Plasma glucose was measured by the hexokinase method using a Beckman AU2700 analyzer (Beckman Coulter, Brea, CA, USA). Serum insulin was assessed by chemiluminescence immunoassay using a Siemens ADIVA Centaur XP analyzer (Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA). The glucose and insulin assays were standardized to NIST SRM 965 and WHO 1st IRP 66/304, respectively. The repeatability and within laboratory coefficient variations were \< 5%.

Classification of glucose tolerance status {#Sec5}
------------------------------------------

According to the World Health Organization definition \[[@CR5], [@CR15], [@CR16]\], normal glucose tolerance (NGT) was defined as FPG \< 6.1 mmol/L and 2-h plasma glucose \< 7.8 mmol/L. Prediabetes was defined as having IFG (FPG: 6.1--6.9 mmol/L) and/or IGT (2-h plasma glucose: 7.8--11.0 mmol/L). Diabetes was defined as having FPG ≥7.0 mmol/l and/or 2-h plasma glucose ≥11.1 mmol/L.

Classification of glucose curve shapes {#Sec6}
--------------------------------------

The shapes were classified in line with previous studies \[[@CR17]\]. A monophasic response curve was determined by a gradual increase in glucose concentrations until a peak was reached, followed by a subsequent decrease in glucose of ≥0.25 mmol/L. A biphasic response curve was defined by the second rise in glucose concentrations of ≥0.25 mmol/L. A triphasic response curve was defined by two complete peaks of the plasma glucose curve, with every rise and decrease in glucose concentrations of ≥0.25 mmol/L. The latter two were collectively called multiphasic response curve. This was done with a plasma glucose threshold of 0.25 mmol/L to minimize fluctuations in glucose concentrations, which may be caused by the method of glucose analysis rather than by physiological reasons.

Calculation of variables {#Sec7}
------------------------

Areas under the glucose and insulin curves were calculated with the trapezoidal rule \[[@CR10]\]. Insulin action was estimated by the homeostasis model assessment for insulin resistance (HOMA-IR) and the whole-body insulin sensitivity index of Matsuda. HOMA-IR = (I~0~-G~0~)/22.5, with glucose and insulin expressed as mmol/L and mUI/ml, respectively \[[@CR18]\]. The Matsuda Index = 10,000/√\[(fasting glucose (mg/dl) × FINS (μU/ml)) × (mean glucose (mg/dl) × mean insulin (μU/ml)\] \[[@CR19]\]. Insulin secretion was estimated by the insulinogenic index. The insulinogenic index was calculated using fasting and 30-min insulin and glucose concentrations \[[@CR20]\]. β-cell function was estimated by the disposition index as the product of insulinogenic index and HOMA-IR \[[@CR21]\].

Statistical analysis {#Sec8}
--------------------

Summary statistics were calculated using frequencies and proportions for categorical data and means (standard deviations) for continuous variables. Kruskal-Wallis, Pearson χ^2^, and unpaired Student's t-tests were used for comparisons. Analysis of covariance was used to compare two glucose response curve groups (monophasic vs. multiphasic) after adjusting for the potential confounding effects (age, sex, glycemic status). A two-sided *p*-value \< 0.05 was considered to indicate statistical significance.

All data were analyzed using IBM SPSS Statistics, version 25. The authors have full access to and take full responsibility for the integrity of the data. The manuscript has been read and approved by all the authors.

Results {#Sec9}
=======

Baseline characteristics according to glucose curve shapes {#Sec10}
----------------------------------------------------------

A total of 9059 OGTTs in 8391 study individuals were included in the final analysis (Fig. [1](#Fig1){ref-type="fig"}). The baseline age was 38.2 ± 13.6 years, and 74.4% were female. In terms of the shape of the participants' OGTT glucose response curve, 87.3% were monophasic, 6.1% were biphasic, and 6.6% were triphasic. Although the individuals with a triphasic curve had better insulin sensitivity and β-cell function than those with a biphasic curve (Table [1](#Tab1){ref-type="table"}), in view of the limited cases, the triphasic group and the biphasic group were collectively referred to as the multiphasic group. Physical and glucose metabolic characteristics of participants with monophasic and multiphasic curves are presented in Table [1](#Tab1){ref-type="table"}. Figure [2](#Fig2){ref-type="fig"} illustrates the average glucose at each point in the monophasic, biphasic, and triphasic curves. The monophasic group exhibited significantly higher FPG (5.6 ± 13.5 vs. 5.2 ± 0.6), 2hPG (8.2 ± 3.2 vs. 6.3 ± 2.0), fasting serum insulin (FINS), and 2 h serum insulin (2 h INS) than the multiphasic group. The monophasic group had a significantly higher HOMA-IR (3.8 ± 2.6 vs. 3.1 ± 2.0) and lower Matsuda Index (2.9 ± 1.9 vs. 3.8 ± 2.5) and insulinogenic index (25.1 ± 23.0 vs. 16.6 ± 17.8). Disposition index, the indicator of β-cell function, was nearly 42% lower in the monophasic group (Table [1](#Tab1){ref-type="table"}). These differences remained significant after adjusting for sex and age. Fig. 1Study Flow Diagram OGTT: oral glucose tolerance test Table 1Demographic and metabolic characteristics of 9059 participants with monophasic versus multiphasic OGTT glucose response curve and 1150 participants with biphasic versus triphasicVariablesMonophasic group\
(*n* = 7909)Multiphasic group\
(*n* = 1150)*P* valueBiphasic group\
(*n* = 548)Triphasic group\
(*n* = 602)*P* valueAge (years)38.6 ± 13.635.4 ± 13.5\< 0.00135.1 ± 13.735.8 ± 13.20.391Sex (male/female), n%2100 (26.6)/5809 (73.4)219 (19.0)/931 (81.0)\< 0.001106 (19.3)/442 (80.7)113 (18.8)/489 (81.2)0.805FBG (mmol/L)5.6 ± 13.55.2 ± 0.6\< 0.0015.2 ± 0.65.2 ± 0.60.18930 min GLU (mmol/L)9.5 ± 2.08.3 ± 1.6\< 0.0018.4 ± 1.68.2 ± 1.6\<0.0012 h GLU (mmol/L)8.2 ± 3.26.3 ± 2.0\< 0.0015.4 ± 1.87.2 ± 1.9\<0.001FINS14.8 ± 8.713.5 ± 7.9\< 0.00113.2 ± 8.413.7 ± 7.50.32830 min INS97.7 ± 59.6123.5 ± 67.1\< 0.001105.6 ± 62.0139.7 ± 67.5\<0.0012 h INS106.9 ± 66.976.8 ± 57.8\< 0.00154.7 ± 43.296.8 ± 62.0\<0.001Glycemic status(%) NGT4253 (53.8)903 (78.5)486 (88.7)417 (69.3) IFG/IGT/IFG + IGT2362 (29.9)206 (17.9)\< 0.00150 (9.1)156 (25.9)\<0.001 DM1294 (16.3)41 (3.6)12 (2.2)29 (4.8)Glucose AUC (mg·dL ^−1^· h ^−1^)1473.5 ± 437.11181.2 ± 257.8\< 0.0011180.0 ± 259.71182.4 ± 256.20.876Insulin AUC (mg·dL ^−1^· h ^− 1^)16,299.7 ± 8297.513,968.7 ± 7498.6\< 0.00113,182.2 ± 7277.714,684.7 ± 7629.90.001HOMA-IR3.8 ± 2.63.1 ± 2.0\< 0.0013.1 ± 2.13.2 ± 1.80.595Matsuda Index2.9 ± 1.93.8 ± 2.5\< 0.0014.0 ± 2.73.6 ± 2.30.018Insulinogenic index25.1 ± 23.042.9 ± 37.7\< 0.00136.0 ± 35.949.1 ± 38.2\<0.001Disposition index12.7 ± 14.116.6 ± 17.8\< 0.00113.7 ± 15.419.2 ± 19.4\<0.001Values are reported as the mean ± SD or n (%). *FBG* fasting blood glucose, *30 min GLU* glucose at 30 min, *2 h GLU* glucose at 120 min, *FINS* fasting insulin, *30 min INS* insulin at 30 min, *2 h INS* insulin at 1200 min, *NGT* normal glucose tolerance, *IFG* impaired fasting glucose, *IGT* impaired glucose tolerance, *DM* diabetes mellitus, *AUC* area under the curve Fig. 2Glucose during a 3-h OGTT in monophasic, biphasic and triphasic groups among different glycemic status. NGT: normal glucose tolerance, DM: diabetes mellitus

Comparison of the glucose curve shapes among different age groups {#Sec11}
-----------------------------------------------------------------

To explore the relationship between age and the shape of the OGTT curve, we divided age into six categories (Fig. [3](#Fig3){ref-type="fig"}). We found that a higher proportion of younger people belonged to the multiphasic group, i.e., a significantly higher proportion of participants aged 18 to 30 years (16.8%) were in the multiphasic group compared with all the other, older groups (30--40 years: 12.2%, 40--50 years: 9.4%, 50--60 years: 9.1%, ≥60 years: 10.7%) (*p* \< 0.001). Furthermore, we divided each age group into three glycemic stages (NGT, prediabetes, DM) to adjust the effect of age on glycemic status (Fig. [3](#Fig3){ref-type="fig"}). When participants were in NGT or prediabetes, younger individuals had a higher proportion of multiphasic curves. However, when the glycemic status progressed to diabetes, quite a low percentage of individuals in all age groups had multiphasic curves. Fig. 3Proportion of multiphasic curves at different age group and glycemic status NGT: normal glucose tolerance, DM: diabetes mellitus

Types of glucose curve shape as the indicator for insulin resistance and β-cell function {#Sec12}
----------------------------------------------------------------------------------------

Surrogate markers of insulin sensitivity and β-cell function including HOMA-IR, Matsuda Index, insulinogenic index, and disposition index were significantly different between the monophasic and multiphasic groups (Table [1](#Tab1){ref-type="table"}). After stratification in glycemic status, the difference in insulinogenic index remained significant at every status of glycemic metabolism. However, the other three indexes no longer showed significant differences in individuals with DM. In addition, no significant differences between the two groups were noted for HOMA-IR in participants with prediabetes (Table [2](#Tab2){ref-type="table"}). Table 2Demographic and metabolic characteristics of 9059 participants with monophasic versus multiphasic OGTT-glucose response curve in different glycemic statusNGT(*n* = 5156)Prediabetes(*n* = 2568)DM(*n* = 1334)Monophasic\
(*n* = 4253)Multiphasic\
(*n* = 903)PMonophasic\
(*n* = 2362)Multiphasic\
(*n* = 206)PMonophasic\
(*n* = 1293)Multiphasic\
(*n* = 41)PAge (years)35.1 ± 12.333.9 ± 12.50.00841.3 ± 13.640.1 ± 15.40.21345.2 ± 13.746.3 ± 13.90.598Sex (male/female), n%963 (22.6)/3290 (77.4)159 (17.6)/744 (82.4)0.001682 (28.9)/1680 (71.1)53 (25.7)/153 (74.3)0.338455 (35.2)/838 (64.8)7 (17.1)/34 (82.9)0.016FBG (mmol/L)5.1 ± 0.55.1 ± 0.4\< 0.0015.6 ± 0.65.5 ± 0.6\< 0.0017.0 ± 1.76.4 ± 1.20.94330 min (mmol/L)8.5 ± 1.37.9 ± 1.3\< 0.0019.9 ± 1.59.3 ± 1.3\< 0.00111.9 ± 2.412.0 ± 2.20.9622hPG (mmol/L)6.1 ± 0.95.6 ± 1.2\< 0.0017.8 ± 1.78.8 ± 1.2\< 0.00113.8 ± 3.312.6 ± 2.70.017FINS13.8 ± 8.013.0 ± 7.70.00815.6 ± 8.515.2 ± 8.40.57817.0 ± 10.415.3 ± 8.00.30130 min INS112.0 ± 61.6124.1 ± 68.0\< 0.00191.9 ± 54.4127.9 ± 63.5\< 0.00161.7 ± 42.887.9 ± 53.60.0032 h INS88.1 ± 57.066.7 ± 50.5\< 0.001133.8 ± 68.7115.9 ± 67.8\< 0.001119.9 ± 73.7100.6 ± 64.30.098Glucose AUC(mg·dL ^−1^· h ^−1^)1197.1 ± 158.01094.1 ± 152.8\< 0.0011563.7 ± 163.91398.0 ± 158.4\< 0.0012219.0 ± 462.62010.2 ± 368.50.004Insulin AUC(mg·dL ^−1^· h ^− 1^)15,411.0±7733.013,198.7±7054.3\< 0.00118,336.3±8582.017,218.6±8506.10.07315,514.8±8888.914,599.2±7349.00.514HOMA-IR3.2 ± 1.93.0 ± 1.80.0023.9 ± 2.33.7 ± 2.10.1995.4 ± 4.14.4 ± 2.80.138Matsuda Index3.3 ± 1.94.1 ± 2.6\< 0.0012.5 ± 1.62.8 ± 1.50.0042.3 ± 1.82.6 ± 1.40.419Insulinogenic index33.1 ± 26.646.4 ± 39.6\< 0.00119.2 ± 13.532.9 ± 26.7\< 0.0019.4 ± 7.813.9 ± 10.3\< 0.001Disposition index15.1 ± 16.017.0 ± 18.20.00111.7 ± 11.716.5 ± 17.0\< 0.0016.9 ± 8.57.6 ± 7.10.594Values are reported as the mean ± SD or n (%). *NGT* normal glucose tolerance, *DM* diabetes mellitus, *FBG* fasting blood glucose, *30 min GLU* glucose at 30 min, *2 h GLU* glucose at 120 min, *FINS* fasting insulin, *30 min INS* insulin at 30 min, *2 h INS* insulin at 1200 min, *AUC* area under the curve

OGTT glucose peak time, nadir time, and insulin peak time in relation to insulin resistant and β-cell function {#Sec13}
--------------------------------------------------------------------------------------------------------------

The multiphasic group could be further divided into two categories by the time when glucose is lowest. The triphasic curve all reached the nadir at 1 h, while the biphasic curve's nadir time could be 1 h or 2 h. Regarding β-cell function, the curve with a nadir time of 2 h had significantly lower insulinogenic index and disposition index (Table [3](#Tab3){ref-type="table"}). But there was no marked difference between the two groups for the HOMA-IR and Matsuda Index. Early glucose and insulin peak times were all associated with lower HOMA-IR (*p* \< 0.001) and a higher disposition index (*p* \< 0.001) (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). Table 3Demographic and metabolic characteristics of 1150 participants with OGTT glucose nadir at 60 min versus at 120 minOGTT glucose nadir at 60 min\
(*n* = 688)OGTT glucose nadir at 120 min\
(*n* = 462)PAge (years)35.5 ± 13.235.3 ± 13.80.824Sex (male/female), n%119 (17.3)/569 (82.7)100 (21.6)/362 (78.4)0.066FBG (mmol/L)5.2 ± 0.65.2 ± 0.60.06930 min GLU(mmol/L)8.2 ± 1.68.5 ± 1.60.0042 h GLU(mmol/L)7.1 ± 2.05.2 ± 1.6\<0.001FINS13.5 ± 7.413.4 ± 8.60.74330 min INS137.7 ± 67.5102.3 ± 60.6\<0.0012 h INS92.6 ± 61.353.2 ± 42.3\<0.001Glycemic status(%) NGT(%)489 (71.1)414 (89.6) IFG/IGT/IFG + IGT(%)167 (24.3)39 (8.4)\< 0.001 DM(%)32 (4.7)9 (1.9)Glucose AUC (mg·dL ^−1^· h ^−1^)1175.3 ± 267.01190.0 ± 243.40.342Insulin AUC(mg·dL ^− 1^· h ^− 1^)14,349.1 ± 7572.713,402.2 ± 7358.60.036HOMAIR3.1 ± 1.83.1 ± 2.20.957Matsuda Index3.8 ± 2.53.8 ± 2.40.670Insulinogenic index49.7 ± 40.832.7 ± 29.7\<0.001Disposition index18.8 ± 19.013.1 ± 15.3\<0.001Values are reported as the mean ± SD or n (%). *FBG* fasting blood glucose, *30 min GLU* glucose at 30 min, *2 h GLU* glucose at 120 min, *FINS* fasting insulin, *30 min INS* insulin at 30 min, *2 h INS* insulin at 1200 min, *NGT* normal glucose tolerance, *IFG* impaired fasting glucose, *IGT* impaired glucose tolerance, *DM* diabetes mellitus, *AUC* area under the curve Table 4Demographic and metabolic characteristics of 9059 participants with OGTT glucose peak at 30 min, 60 min versus 120 minOGTT glucose peak at 30 min\
(*n* = 4599)OGTT glucose peak at 60 min\
(*n* = 3912)OGTT glucose peak at 120 min\
(*n* = 548)PAge (years)35.8 ± 12.840.1 ± 13.644.9 ± 14.9\<0.001Sex (male/female), n%974 (21.2)/3625 (78.8)1178 (30.1)/2734 (69.9)167 (30.5)/381 (69.5)\<0.001FBG(mmol/L)5.2 ± 0.65.7 ± 1.16.6 ± 2.0\<0.00130 min GLU(mmol/L)8.8 ± 1.69.8 ± 2.110.6 ± 3.0\<0.0012 h GLU(mmol/L)6.3 ± 1.58.9 ± 2.814.4 ± 4.3\<0.001FINS13.6 ± 7.715.6 ± 9.216.5 ± 10.3\<0.00130 min INS121.8 ± 63.682.0 ± 50.162.6 ± 48.3\<0.0012 h INS85.9 ± 58.8121.5 ± 68.9116.0 ± 73.2\<0.001Glycemic status(%) NGT(%)3749 (81.5)1386 (35.4)21 (3.8) IFG/IGT/IFG + IGT(%)766 (16.7)1693 (43.3)109 (19.9)\< 0.001 DM(%)84 (1.8)833 (21.3)418 (76.3)Glucose AUC (mg·dL ^−1^· h ^−1^)1202.6 ± 212.31609.3 ± 385.42163.9 ± 643.5\<0.001Insulin AUC(mg·dL ^−1^· h ^− 1^)15,048.7 ± 7705.217,313.6 ± 8561.214,668.6 ± 8865.8\<0.001HOMAIR3.2 ± 1.94.1 ± 2.84.9 ± 3.9\<0.001Matsuda Index3.4 ± 2.12.6 ± 1.72.8 ± 2.1\<0.001Insulinogenic index36.1 ± 30.018.8 ± 16.215.0 ± 20.9\<0.001Disposition index15.6 ± 16.211.0 ± 12.48.6 ± 12.6\<0.001Values are reported as the mean ± SD or n (%). *FBG* fasting blood glucose, *30 min GLU* glucose at 30 min, *2 h GLU* glucose at 120 min, *FINS* fasting insulin, *30 min INS* insulin at 30 min, 2 h *INS* insulin at 1200 min, *NGT* normal glucose tolerance, *IFG* impaired fasting glucose, *IGT* impaired glucose tolerance, *DM* diabetes mellitus, *AUC* area under the curve Table 5Demographic and metabolic characteristics of 9059 participants with OGTT insulin peak at 30 min, 60 min versus 120 minOGTT insulin peak at 30 min\
(*n* = 2935)OGTT insulin peak at 60 min\
(*n* = 3729)OGTT insulin peak at 120 min\
(*n* = 2279)OGTT insulin peak at 180 min\
(*n* = 116)PAge (years)36.1 ± 13.537.9 ± 13.141.3 ± 13.939.7 ± 14.4\<0.001Sex (male/female), n%610 (20.8)/2325 (79.2)1073 (28.8)/2656 (71.2)611 (26.8)/1668 (73.2)25 (21.2)/91 (78.8)\<0.001FBG(mmol/L)5.2 ± 1.05.5 ± 1.05.9 ± 1.26.3 ± 1.6\<0.00130 min GLU(mmol/L)8.6 ± 1.79.4 ± 2.010.1 ± 2.010.2 ± 2.6\<0.0012 h GLU(mmol/L)6.9 ± 2.47.1 ± 2.610.3 ± 3.312.9 ± 4.2\<0.001FINS13.7 ± 7.914.8 ± 8.815.5 ± 8.817.2 ± 11.2\<0.00130 min INS133.0 ± 66.195.4 ± 54.971.3 ± 43.756.4 ± 35.1\<0.0012 h INS85.5 ± 59.789.6 ± 56.4147.2 ± 70.6117.0 ± 62.9\<0.001Glycemic status(%) NGT(%)2211 (75.3)2514 (67.4)424 (18.6)7 (5.3) IFG/IGT/IFG + IGT(%)549 (18.7)893 (24.0)1089 (47.8)38 (32.7)\< 0.001 DM(%)175 (6.0)322 (8.6)766 (33.6)71 (61.9)Glucose AUC (mg·dL ^−1^· h ^−1^)1239.8 ± 329.61389.2 ± 362.01738.5 ± 440.92070.4 ± 580.7\<0.001Insulin AUC(mg·dL ^−1^· h ^− 1^)14,403.2 ± 7536.116,046.0 ± 8141.517,980.4 ± 8741.517,006.3 ± 8977.3\<0.001HOMAIR3.3 ± 2.13.7 ± 2.64.2 ± 2.85.1 ± 4.5\<0.001Matsuda Index3.5 ± 2.22.9 ± 1.92.6 ± 1.82.8 ± 2.6\<0.001Insulinogenic index41.8 ± 33.423.9 ± 19.415.1 ± 13.511.7 ± 10.2\<0.001Disposition index17.4 ± 17.612.7 ± 13.59.0 ± 10.76.7 ± 7.1\<0.001Values are reported as the mean ± SD or n (%). *FBG* fasting blood glucose, *30 min GLU* glucose at 30 min, *2 h GLU* glucose at 120 min, *FINS* fasting insulin, *30 min INS* insulin at 30 min, *2 h INS* insulin at 1200 min, *NGT* normal glucose tolerance, *IFG* impaired fasting glucose, *IGT* impaired glucose tolerance, *DM* diabetes mellitus, *AUC* area under the curve

Change in the OGTT glucose curve shape and risk of impaired glucose metabolism {#Sec14}
------------------------------------------------------------------------------

There were 635 participants who underwent OGTT twice. Table [5](#Tab5){ref-type="table"} shows baseline physical and metabolic characteristics of all the participants with a stable glucose response curve shape compared to those with unstable shape. Of the participants, 80.3% exhibited no change in shape between the baseline and the second OGTT (Table [6](#Tab6){ref-type="table"}). Individuals who maintained a monophasic glucose response curve had the lowest rate of NGT, and those who maintained a multiphasic glucose response curve had the highest rate of NGT at baseline. Individuals with a stable monophasic glucose response shape had significantly higher fasting and 2hPG. Persistence of the monophasic shape was, in general, associated with worse insulin sensitivity and reduced β-cell function. Individuals whose glucose response curve changed from multiphasic to monophasic tended to have a higher rate of deterioration in glucose metabolism (Table [7](#Tab7){ref-type="table"}). Table 6Demographic and metabolic characteristics of 502 participants with stable versus unstable OGTT-glucose response curveStableUnstable*P* valueMonophasicMultiphasicMonophasic to MultiphasicMultiphasic to MonophasicN37195567Age (years)35.5 ± 12.337.0 ± 11.332.9 ± 13.235.1 ± 14.60.535Sex (male/female, %)62 (16.7)/309 (83.3)2 (22.2)/7 (77.8)9 (16.4)/46 (83.6)9 (13.4)/58 (86.6)0.878FBG(mmol/L)5.6 ± 0.95.1 ± 0.65.2 ± 0.65.2 ± 0.5\< 0.00130 min GLU(mmol/L)9.2 ± 1.78.2 ± 1.48.5 ± 1.38.3 ± 1.4\< 0.0012 h GLU(mmol/L)8.1 ± 2.75.6 ± 1.26.5 ± 1.66.5 ± 1.7\< 0.001FINS17.7 ± 9.211.1 ± 5.315.4 ± 10.016.8 ± 9.70.07530 min INS111.2 ± 65.3152.8 ± 69.7131.2 ± 74.8150.2 ± 67.7\< 0.0012 h INS128.8 ± 72.269.3 ± 46.7101.7 ± 66.997.0 ± 65.7\< 0.001Glycemic status(n,%) NGT181 (48.8)9 (100)42 (76.4)51 (76.1) IFG/IGT/IFG + IGT145 (39.1)012 (21.8)16 (23.9)\< 0.001 DM45 (12.1)01 (1.8)0Glucose AUC(mg·dL ^−1^· h ^−1^)1461.3 ± 366.01100.2 ± 83.11230.5 ± 231.01184.8 ± 208.6\< 0.001Insulin AUC(mg·dL ^−1^· h ^− 1^)19,184.5 ± 8734.113,817.2 ± 5128.217,677.0 ± 90,944.718,637.6 ± 8730.20.068HOMA-IR4.4 ± 2.62.6 ± 1.23.6 ± 2.43.9 ± 2.30.012Matsuda Index2.4 ± 1.63.8 ± 2.33.1 ± 2.03.1 ± 2.0\< 0.001Insulinogenic index29.6 ± 28.352.8 ± 34.137.7 ± 23.755.2 ± 56.7\< 0.001Disposition index17.2 ± 17.316.3 ± 7.019.2 ± 18.224.3 ± 20.40.025Values are reported as the mean ± SD or n (%). *FBG* fasting blood glucose, *30 min GLU* glucose at 30 min, *2 h GLU* glucose at 120 min, *FINS* fasting insulin, *30 min INS* insulin at 30 min, *2 h INS* insulin at 1200 min, *NGT* normal glucose tolerance, *IFG* impaired fasting glucose, *IGT* impaired glucose tolerance, *DM* diabetes mellitus, *AUC* area under the curve Table 7The relationship between the change of the phase number and the change of the glycemic statusGlycemic statusImproveUnchangingAggravationTotalChange of the phase-numberDecrease7 (10.4%)49 (73.1%)11 (16.4%)67Unchanging65 (17.1%)245 (64.5%)70 (18.4%)380Increase11 (20.0%)38 (69.1%)6 (10.9%)55Total8333287502Values are reported as N (n%)

Discussion {#Sec15}
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The present investigation revealed the following findings regarding the shape of OGTT curve in a large Chinese population: 1) multiphasic OGTT response curves were not rare in Chinese people, accounting for more than 10% of the population; 2) monophasic curves were more common in older people and in those with worse glycemic status; 3) individuals with monophasic curves had poorer β-cell function than individuals with multiphasic curves, despite having similar glycemic status; 4) individuals who were in NGT with a monophasic shape showed significantly worse insulin sensitivity, as reflected by the HOMA-IR and Matsuda Index, compared to patients with a multiphasic curve; 5) β-cell function was better in patients whose glucose concentration started to decrease at 60 min compared to later among the multiphasic curve group; and 6) the number of phases of the same subject could change at different times, and the number of phases increased with the improvement of glucose status.

In studies of nondiabetic individuals, the morphology of the monophasic glucose response curve is the dominant phenotype, up to 57--84% in adults \[[@CR12], [@CR13], [@CR17], [@CR22], [@CR23]\] and 35--69% in obese youth at high risk for T2D \[[@CR6], [@CR7], [@CR9], [@CR10], [@CR24]\]. Our study showed that about 88.3% of individuals had monophasic response curves and 11.7% had multiphasic response curves. Combining our present research with previous studies in youth \[[@CR6], [@CR10]\] and adults \[[@CR12]\], the multiphasic group tends to be associated with younger age compared with the monophasic group. Our study further found that there was little difference between the two glucose curve shape groups when the glycemic status reached diabetes, and both young and old individuals had an extremely low proportion of multiphasic OGTT response curve.

Cross-sectional studies in youths \[[@CR6]--[@CR13]\] and adults \[[@CR11]--[@CR13], [@CR23]\] showed that the shape of the OGTT glucose response curve could indicate insulin sensitivity and β-cell function, as well as differentiate type 2 diabetes risk. Obese youths with monophasic glucose response curves were worse in both hepatic and peripheral insulin sensitivity measured by the clamp method compared with the biphasic group, as well as in β-cell function, which was indicated by impaired disposition index as a result of lacking in a compensatory increase in first and second-phase insulin secretion \[[@CR6]\]. Evidence from patients with suspected gestational diabetes who underwent 3 h OGTT showed that a greater number of phases in the OGTT glucose response curve was associated with a healthier metabolic state, which suggests that a biphasic response curve may be associated with a lower incidence of prediabetes and T2D \[[@CR13]\]. In our study, β-cell function was better in individuals with multiphasic glucose response curve. As for insulin sensitivity, the difference was still significant in the NGT group, but the difference did not remain significant in the diabetes group. The most likely reason is that defects in β-cell function are more severe in Chinese patients with diabetes than those in Europeans or Americans, resulting in more serious deficiencies in insulin secretion \[[@CR25]\].

Am American study conducted in adult patients showed that the baseline and subsequent glucose concentrations in the OGTT could stratify the risk for progression to T2D; that is, a faster return to the FPG concentration may suggest a lower risk of T2D \[[@CR22]\]. Our study further found that individuals with multiphasic curves whose plasma glucose concentration reached the lowest point at 60 min had better β-cell function than those with a nadir at 120 min. Consistent with previous studies \[[@CR26]\], we found that the earlier the glucose/insulin peak in the OGTT curve, the better the β-cell function.

Our data showed that individuals whose response glucose curve changed from multiphasic to monophasic during follow-up were more prone to deteriorate in glycemic status than those whose glucose response curves changed from monophasic curves to multiphasic curves. This result is supported by several longitudinal studies. A 7--8 year longitudinal study demonstrated that pre-diabetic patients with monophasic curves had twice the incidence of diabetes as those with biphasic curves, despite similar fasting and 2hPG concentrations \[[@CR22]\]. Individuals with a monophasic curve at baseline and those whose patterns changed from biphasic to monophasic had an increased risk for impaired glucose metabolism \[[@CR14]\]. We also found that individuals with a persistent monophasic curve had worse insulin sensitivity and β-cell function than those with other forms at baseline.

The strengths of the present investigation include the following: 1) it is the first large-scale (up to 10,000) investigation of the relationship between the OGTT glucose response curve and insulin resistance/β-cell function in Chinese people; 2) the study included people with different glucose metabolic states and across different age groups. Potential perceived limitations would be that we have no anthropometric data, such as body mass index (BMI) and waist circumference, which could have an influence on glycemic status. But previous research showed that the OGTT response curve shape remained strongly associated with insulin sensitivity and β-cell function after adjusting for BMI, blood pressure, and waist circumference \[[@CR6], [@CR8]\]. In addition, our research follows the standard methods used in China. The OGTT glucose response curve shape was determined by data only at 0, 30, 60, 120, and 180 min, lacking 90 min glucose data, which may have led to an underestimation in the phase of the curve. Investigations of the change in patterns or shapes of the OGTT glucose response curves did not have regular follow-up.

Conclusions {#Sec16}
===========

In summary, the present study is the first to demonstrate that in a large Chinese population, the monophasic OGTT glucose response curve was associated with reduced β-cell function, higher HOMA-IR, and older age. However, prospective longitudinal studies are needed to verify the usefulness of the OGTT glucose response curve in predicting progression to prediabetes or T2D in Chinese. Further, it remains essential to examine whether any factors could shift the OGTT glucose response curve from monophasic to multiphasic.

2hPG

:   2-h plasma glucose

BMI

:   Body mass index

DM

:   Diabetes mellitus

FINS

:   Fasting serum insulin

FPG

:   Fasting plasma glucose

IFG

:   Impaired fasting glucose

IGT

:   Impaired glucose tolerance

NGT

:   Normal glucose tolerance

OGTT

:   Oral glucose tolerance test

T2D

:   Type 2 diabetes
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